Список проголосовавших за комментарий " On The Wires<ul><li>Tonix Pharmaceuticals Holding Corp. (<strong>TNXP</strong>) announced today that it will present at The MicroCap Conference on April 4, 2017 in New York, NY. Seth Lederman, M.D., president and chief executive officer of Tonix, will provide a corporate update and an overview of Tonix's posttraumatic stress disorder (PTSD) clinical program. TNX-102 SL was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of PTSD. This month, Tonix dosed the first patient for the «HONOR» study, a 12-week placebo-controlled Phase 3 clinical study evaluating TNX-102 SL 5.6 mg, in military-related PTSD. The interim analysis of the HONOR study is expected in the first half of 2018 and topline results are expected in the second half of 2018.</li><li>Attunity Ltd. (<strong>ATTU</strong>) announced that FuseForward, a secure cloud solutions provider, has chosen Attunity Replicate to expand the capabilities of its patented cloud platform. Attunity's real-time data replication and change data capture technology, supporting Kafka and Hadoop, enables a more robust analytics offering and user experience for FuseForward customers.</li></ul>"